Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

10 Triumphant Drug Launches Of The Decade

Executive Summary

The view from 2020: Scrip looks back at the most successful commercial launches of the decade.

You may also be interested in...



Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected

Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.

Pfizer’s 20-Valent Vaccine And Prevnar Successor Succeeds In Phase III

The company still plans to file 20vPnC for US FDA approval by the end of 2020 after the pneumococcal vaccine was non-inferior to Prevnar and to Pneumovax on six additional serotypes in older patients.

J.P. Morgan Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris debuts, BeiGene on US drug pricing and Roche think neuroscience is the new oncology.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141426

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel